Iovance Biotherapeutics, Inc. updated its corporate presentation on November 5, 2026, which includes a revision of its financial outlook for the current year. The company raised its full-year 2026 revenue guidance to $410 million–$420 million from the previous range of $350 million–$370 million. This adjustment reflects strong third-quarter performance, with Q3 revenue reaching approximately $122 million, representing roughly 80% year-over-year growth and a gross margin from cost of sales of about 60%. The company reported a cash position of approximately $382 million as of September 30, 2026, providing a runway well into 2029. Iovance Biotherapeutics operates in the biotechnology industry, specializing in the development and commercialization of tumor-infiltrating lymphocyte (TIL) cell therapies for solid tumors.
